Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity,

[keangkong]

Innovent Biologics (Nov. 19, 2025). Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints. PRNewswire, https://www.prnewswire.com/news-rel...nd-all-key-secondary-endpoints-302620471.html.

Highlights include:

Innovent plans to ask the Chinese version of the FDA to approve a new maximum dosage of 9 mg per week. Currently, the maximum recommended dosage is 6 mg per week.

"Among participants (without type 2 diabetes) with baseline liver fat content ≥10%, the mean percent change in liver fat content from baseline to week 60 was -71.9% in the mazdutide 9 mg group compared with 5.1% in the placebo group." I believe the figure for tirzepatide is an 8% reduction. In other words, GIPR agonism appears necessary in order to dramatically reduce liver fat.

"[A]mong participants without type 2 diabetes, the mazdutide 9 mg group showed a mean weight reduction of 20.08% at Week 60 (placebo: 2.81%) . . ."

"During the treatment period, participants in the mazdutide group exhibited continuous weight loss, with no plateau observed in Week 60."

We just have a press release right now. Eventually we'll get a scholarly article. Perhaps there will a "poster presentation" at an academic conference beforehand.

 

[keangkong]

In contrast, retatrutide obtained a 24% weight loss at 48 weeks (Jastreboff, et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New Eng. J. Med., 389(6), 514–526, https://www.nejm.org/doi/full/10.1056/NEJMoa2301972), 12 weeks less than the 60 weeks studied int he mazdutide study. In the retatrutide study, the 24% represents the percent weight excluding the weight loss on placebo. The closest comparable figure in the mazdutide study is 17%. Still maz's performance is quite impressive.